Bernadette G Van Den Hoogen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8137053/publications.pdf

Version: 2024-02-01

47 papers

6,173 citations

201575 27 h-index 254106 43 g-index

50 all docs

50 docs citations

50 times ranked

6461 citing authors

#	Article	IF	CITATIONS
1	Optimizing environmental safety and cell-killing potential of oncolytic Newcastle Disease virus with modifications of the V, F and HN genes. PLoS ONE, 2022, 17, e0263707.	1.1	2
2	THER-02. Pediatric brain tumor cultures reveal differential susceptibility to four oncolytic viruses. Neuro-Oncology, 2022, 24, i186-i186.	0.6	0
3	Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic adenocarcinoma. Heliyon, 2022, 8, e09915.	1.4	2
4	Clinical impact of human metapneumovirus infections before and during the COVID-19 pandemic. Infectious Diseases, 2021, 53, 1-10.	1.4	17
5	Rintatolimod Induces Antiviral Activities in Human Pancreatic Cancer Cells: Opening for an Anti-COVID-19 Opportunity in Cancer Patients?. Cancers, 2021, 13, 2896.	1.7	5
6	2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2021, 166, 3513-3566.	0.9	62
7	Whole genome sequencing of human metapneumoviruses from clinical specimens using MinION nanopore technology. Virus Research, 2021, 302, 198490.	1.1	3
8	100 days of solitude: The spring of COVID-19 through the eyes of 15 young virologists of the INITIATE program. Virus Research, 2020, 287, 198093.	1.1	2
9	Immunometabolism pathways as the basis for innovative anti-viral strategies (INITIATE): A Marie Sklodowska-Curie innovative training network. Virus Research, 2020, 287, 198094.	1.1	2
10	Determinants of the efficacy of viro-immunotherapy: A review. Cytokine and Growth Factor Reviews, 2020, 56, 124-132.	3.2	1
11	Induction of the Type I IFN Response by Human Metapneumovirus Lacking SH, G, or M2.2 Expression. Proceedings (mdpi), 2020, 50, .	0.2	0
12	2020 taxonomic update for phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales. Archives of Virology, 2020, 165, 3023-3072.	0.9	184
13	Developing oncolytic viruses for clinical use: A consortium approach. Cytokine and Growth Factor Reviews, 2020, 56, 133-140.	3.2	13
14	ADAR1: "Editor-in-Chief―of Cytoplasmic Innate Immunity. Frontiers in Immunology, 2019, 10, 1763.	2.2	137
15	Taxonomy of the order Mononegavirales: second update 2018. Archives of Virology, 2019, 164, 1233-1244.	0.9	70
16	Taxonomy of the order Mononegavirales: update 2019. Archives of Virology, 2019, 164, 1967-1980.	0.9	224
17	Zoonotic Infection With Pigeon Paramyxovirus Type 1 Linked to Fatal Pneumonia. Journal of Infectious Diseases, 2018, 218, 1037-1044.	1.9	11
18	Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine and Growth Factor Reviews, 2018, 41, 28-39.	3.2	110

#	Article	IF	Citations
19	Recovery of a Paramyxovirus, the Human Metapneumovirus, from Cloned cDNA. Methods in Molecular Biology, 2017, 1602, 125-139.	0.4	2
20	Pigeon paramyxovirus type 1 from a fatal human case induces pneumonia in experimentally infected cynomolgus macaques (Macaca fascicularis). Veterinary Research, 2017, 48, 80.	1.1	4
21	Cerebrospinal Fluid Findings in an Adult with Human Metapneumovirus–Associated Encephalitis. Emerging Infectious Diseases, 2017, 23, 370-370.	2.0	10
22	Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses <i>In Vitro</i> and against Human Metapneumovirus in Hamsters. Antimicrobial Agents and Chemotherapy, 2016, 60, 4620-4629.	1.4	39
23	Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Viruses, 2015, 7, 2980-2998.	1.5	33
24	Oncolytic viruses: From bench to bedside with a focus on safety. Human Vaccines and Immunotherapeutics, 2015, 11, 1573-1584.	1.4	98
25	Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture. Antimicrobial Agents and Chemotherapy, 2014, 58, 4875-4884.	1.4	611
26	Excessive production and extreme editing of human metapneumovirus defective interfering RNA is associated with type I IFN induction. Journal of General Virology, 2014, 95, 1625-1633.	1.3	40
27	264. Cytokine, 2013, 63, 305-306.	1.4	0
28	Paramyxovirus infections in ex vivo lung slice cultures of different host species. Journal of Virological Methods, 2013, 193, 159-165.	1.0	25
29	MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment. Journal of General Virology, 2013, 94, 1749-1760.	1.3	313
30	PS1-103 Pancreatic adenocarcinoma: Understanding differences in interferon pathways to optimize oncolytic virotherapy. Cytokine, 2011, 56, 43-44.	1.4	0
31	Human Metapneumovirus: Lessons Learned over the First Decade. Clinical Microbiology Reviews, 2011, 24, 734-754.	5.7	167
32	Immunogenicity and efficacy of two candidate human metapneumovirus vaccines in cynomolgus macaques. Vaccine, 2008, 26, 4224-4230.	1.7	45
33	Specificity and functional interaction of the polymerase complex proteins of human and avian metapneumoviruses. Journal of General Virology, 2008, 89, 975-983.	1.3	13
34	Generation of temperature-sensitive human metapneumovirus strains that provide protective immunity in hamsters. Journal of General Virology, 2008, 89, 1553-1562.	1.3	37
35	Respiratory Tract Infection Due to Human Metapneumovirus among Elderly Patients. Clinical Infectious Diseases, 2007, 44, 1159-1160.	2.9	40
36	Human Bocavirus and Acute Wheezing in Children. Clinical Infectious Diseases, 2007, 44, 904-910.	2.9	508

#	Article	IF	CITATIONS
37	Experimental infection of macaques with human metapneumovirus induces transient protective immunity. Journal of General Virology, 2007, 88, 1251-1259.	1.3	47
38	Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine, 2007, 25, 8518-8528.	1.7	51
39	An improved plaque reduction virus neutralization assay for human metapneumovirus. Journal of Virological Methods, 2007, 143, 169-174.	1.0	41
40	Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. Journal of General Virology, 2007, 88, 2702-2709.	1.3	48
41	Antigenic and Genetic Variability of Human Metapneumoviruses. Emerging Infectious Diseases, 2004, 10, 658-666.	2.0	329
42	Recovery of Human Metapneumovirus Genetic Lineages A and B from Cloned cDNA. Journal of Virology, 2004, 78, 8264-8270.	1.5	92
43	Real-Time Reverse Transcriptase PCR Assay for Detection of Human Metapneumoviruses from All Known Genetic Lineages. Journal of Clinical Microbiology, 2004, 42, 981-986.	1.8	284
44	Clinical impact and diagnosis of human metapneumovirus infection. Pediatric Infectious Disease Journal, 2004, 23, S25-S32.	1.1	251
45	Prevalence and Clinical Symptoms of Human Metapneumovirus Infection in Hospitalized Patients. Journal of Infectious Diseases, 2003, 188, 1571-1577.	1.9	370
46	A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nature Medicine, 2001, 7, 719-724.	15.2	1,821
47	Human Metapneumovirus. , 0, , 51-68.		O